Changes in global patterns of care for first-line advanced nonsquamous (NS) non-small cell lung cancer (NSCLC): 2007-2010

被引：0
|
作者：
Combest, A. J.
Bryan, J. K.
Moseley, A.
Reitsma, D. J.
Scazafave, M.
Wood, J. M.
Iocca, H. A.
Goyo, J.
An, J. S.
Lee, M. W.
机构：
[1] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC USA
[2] PPD Inc, Wilmington, NC USA
[3] Synovate Healthcare, Mahwah, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e16639
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16639
引用
收藏
页数：1
相关论文
共 50 条
  • [31] First-line treatment for non-small cell lung cancer
    Pinn, Stephen
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2011, 72 (01) : 10 - 10
  • [32] Clinical Outcomes of First-line Therapies for Advanced Non-Small Cell Lung Cancer
    Garcia-Fumero, Ricardo
    Fernandez-Lopez, Cristina
    Calleja-Hernandez, Miguel angel
    Exposito-Ruiz, Manuela
    Espin, Jaime
    Exposito-Hernandez, Jose
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2023, 46 (10): : 433 - 438
  • [33] EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
    Fong, Thomas
    Morgensztern, Daniel
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (03) : 303 - 310
  • [34] What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer?
    Ricciuti, Biagio
    Awad, Mark M.
    CANCER JOURNAL, 2020, 26 (06): : 485 - 495
  • [35] Bevacizumab in combination with first-line metastatic chemotherapy in patients with advanced nonsquamous non-small cell lung cancer (NSCLC): Results from the cohort study EOLE.
    Chouaid, Christos
    Schott, Roland
    Falchero, Lionel
    Bonnetain, Franck
    Neaume, Julien
    Bennouna, Jaafar
    Tagieva, Naila
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] Atezolizumab for first-line treatment of metastatic nonsquamous non-small cell lung cancer: what makes the difference?
    Bersanelli, Melissa
    Petrelli, Fausto
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S3241 - S3243
  • [37] A cost-effectiveness analysis of first-line toripalimab plus chemotherapy in advanced nonsquamous non-small cell lung cancer in China
    Zheng, Zhiwei
    Zhu, Gaofeng
    Cao, Xueqiong
    Cai, Hongfu
    Zhu, Huide
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2023, 16 (03) : 267 - 273
  • [38] Nutritional status changes in patients with advanced non-small cell lung cancer receiving first-line chemotherapy
    Wei Sun
    Shunfang Liu
    Ping Peng
    Dongbo Liu
    OncologyandTranslationalMedicine, 2018, 4 (02) : 54 - 57
  • [39] Penpulimab in combination with anlotinib as first-line treatment in advanced nonsquamous non-small-cell lung cancer.
    Han, Baohui
    Chen, Jianhua
    Wang, Ziping
    Li, Xingya
    Wang, Lin
    Wu, Lin
    Xie, Qiang
    Zhao, Yanqiu
    Wang, Mengzhao
    Lu, Junguo
    Shi, Huaqiu
    Ye, Feng
    Mei, Xiaodong
    Yao, Weirong
    Yue, Lu
    Jiang, Da
    Zhao, Jian
    Zhang, Shucai
    Chen, Gongyan
    Jiao, Shunchang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer
    Sugawara, S.
    Lee, J-S
    Kang, J-H
    Kim, H. R.
    Inui, N.
    Hida, T.
    Lee, K. H.
    Yoshida, T.
    Tanaka, H.
    Yang, C-T
    Nishio, M.
    Ohe, Y.
    Tamura, T.
    Yamamoto, N.
    Yu, C-J
    Akamatsu, H.
    Namba, Y.
    Sumiyoshi, N.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2021, 32 (09) : 1137 - 1147
12345